Literature DB >> 19767764

Characterization of cardamonin metabolism by P450 in different species via HPLC-ESI-ion trap and UPLC-ESI-quadrupole mass spectrometry.

Yu-Qi He1, Li Yang, Yong Liu, Jiang-Wei Zhang, Jun Tang, Juan Su, Yuan-Yuan Li, Yan-Liu Lu, Chang-Hong Wang, Ling Yang, Zheng-Tao Wang.   

Abstract

AIM: To characterize the metabolism of cardamonin by the P450 enzymes in human and animal liver microsomes.
METHODS: Cardamonin was incubated with both human and animal liver microsomal incubation systems containing P450 reaction factors. High performance liquid chromatography coupled with ion trap mass spectrometry was used to identify the metabolites. Serial cardamonin dilutions were used to perform a kinetic study in human liver microsomes. Selective inhibitors of 7 of the major P450 isozymes were used to inhibit cardamonin hydroxylation to identify the isozymes involved in cardamonin metabolism. The cardamonin hydroxylation metabolic capacities of human and various other animals were investigated using the liver microsomal incubation system.
RESULTS: Two metabolites generated by the liver microsome system were detected and identified as hydroxylated cardamonin. The Km and Vmax values for cardamonin hydroxylation were calculated as 32 micromol/L and 35 pmol x min(-1) x mg(-1), respectively. Furafylline and clomethiazole significantly inhibited cardamonin hydroxylation. Guinea pigs showed the highest similarity to humans with respect to the metabolism of cardamonin.
CONCLUSION: CYP 1A2 and 2E1 were identified as the P450 isozymes involved in the metabolism of cardamonin in human liver microsomes. Furthermore, our research suggests that guinea pigs could be used in the advanced pharmacokinetic studies of cardamonin in vivo.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19767764      PMCID: PMC4007323          DOI: 10.1038/aps.2009.127

Source DB:  PubMed          Journal:  Acta Pharmacol Sin        ISSN: 1671-4083            Impact factor:   6.150


  35 in total

1.  Metabolism of apigenin by rat liver phase I and phase ii enzymes and by isolated perfused rat liver.

Authors:  Angéline Gradolatto; Marie-Chantal Canivenc-Lavier; Jean-Philippe Basly; Marie-Hélène Siess; Caroline Teyssier
Journal:  Drug Metab Dispos       Date:  2004-01       Impact factor: 3.922

2.  The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective.

Authors:  Thorir D Bjornsson; John T Callaghan; Heidi J Einolf; Volker Fischer; Lawrence Gan; Scott Grimm; John Kao; S Peter King; Gerald Miwa; Lan Ni; Gondi Kumar; James McLeod; R Scott Obach; Stanley Roberts; Amy Roe; Anita Shah; Fred Snikeris; John T Sullivan; Donald Tweedie; Jose M Vega; John Walsh; Steven A Wrighton
Journal:  Drug Metab Dispos       Date:  2003-07       Impact factor: 3.922

3.  Oxidative metabolism of the soy isoflavones daidzein and genistein in humans in vitro and in vivo.

Authors:  S E Kulling; D M Honig; M Metzler
Journal:  J Agric Food Chem       Date:  2001-06       Impact factor: 5.279

4.  Determination of flavone, flavonol, and flavanone aglycones by negative ion liquid chromatography electrospray ion trap mass spectrometry.

Authors:  N Fabre; I Rustan; E de Hoffmann; J Quetin-Leclercq
Journal:  J Am Soc Mass Spectrom       Date:  2001-06       Impact factor: 3.109

5.  Bioflavonoids: selective substrates and inhibitors for cytochrome P450 CYP1A and CYP1B1.

Authors:  H Doostdar; M D Burke; R T Mayer
Journal:  Toxicology       Date:  2000-04-03       Impact factor: 4.221

Review 6.  The use of in vitro methods to predict in vivo pharmacokinetics and drug interactions.

Authors:  K A Bachmann; R Ghosh
Journal:  Curr Drug Metab       Date:  2001-09       Impact factor: 3.731

7.  In vitro investigation of cytochrome P450-mediated metabolism of dietary flavonoids.

Authors:  V M Breinholt; E A Offord; C Brouwer; S E Nielsen; K Brøsen; T Friedberg
Journal:  Food Chem Toxicol       Date:  2002-05       Impact factor: 6.023

8.  Metabolism of biochanin A and formononetin by human liver microsomes in vitro.

Authors:  William H Tolleson; Daniel R Doerge; Mona I Churchwell; M Matilde Marques; Dean W Roberts
Journal:  J Agric Food Chem       Date:  2002-08-14       Impact factor: 5.279

9.  [Studies on the constituents of Alpinia. XII. On the constituents of the seeds of Alpinia katsumadai hayata. I. The structure of cardamomin].

Authors:  Y Kimura; S Takahashi; I Yoshida
Journal:  Yakugaku Zasshi       Date:  1968-02       Impact factor: 0.302

10.  Validated assays for human cytochrome P450 activities.

Authors:  Robert L Walsky; R Scott Obach
Journal:  Drug Metab Dispos       Date:  2004-06       Impact factor: 3.922

View more
  4 in total

1.  An overview on cardamonin.

Authors:  Luís Moreira Gonçalves; Inês Maria Valente; José António Rodrigues
Journal:  J Med Food       Date:  2014-01-16       Impact factor: 2.786

2.  An In-Depth Study on the Metabolite Profile and Biological Properties of Primula auriculata Extracts: A Fascinating Sparkle on the Way from Nature to Functional Applications.

Authors:  Inci Kurt-Celep; Dimitrina Zheleva-Dimitrova; Reneta Gevrenova; Abdullahi Ibrahim Uba; Gokhan Zengin; Evren Yıldıztugay; Carene Marie Nancy Picot-Allain; José Manuel Lorenzo; Mohamad Fawzi Mahomoodally; Domenico Montesano
Journal:  Antioxidants (Basel)       Date:  2022-07-15

3.  In vitro inhibitory effects of cepharanthine on human liver cytochrome P450 enzymes.

Authors:  Xunge Zhang; Ping Feng; Xinfu Gao; Bin Wang; Chunxia Gou; Ruimin Bian
Journal:  Pharm Biol       Date:  2020-12       Impact factor: 3.503

Review 4.  Mechanistic insights into dimethyl cardamonin-mediated pharmacological effects: A double control of the AMPK-HMGB1 signaling axis.

Authors:  Christian Bailly; Gérard Vergoten
Journal:  Life Sci       Date:  2020-10-18       Impact factor: 5.037

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.